What is Wedbush’s Forecast for KROS Q4 Earnings?

Keros Therapeutics, Inc. (NASDAQ:KROS) – Wedbush issued their Q4 2025 earnings estimates for Keros Therapeutics in a research report issued on Monday, November 4th. Wedbush analyst Y. Zhong forecasts that the company will post earnings of ($1.27) per share for the quarter. Wedbush has a “Strong-Buy” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.90) per share.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The business had revenue of $0.04 million during the quarter. During the same period in the previous year, the firm posted ($1.27) earnings per share.

A number of other research analysts also recently weighed in on KROS. Jefferies Financial Group started coverage on Keros Therapeutics in a research note on Tuesday. They issued a “buy” rating on the stock. Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective for the company. Scotiabank assumed coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price on the stock. Cantor Fitzgerald assumed coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They set an “overweight” rating for the company. Finally, Bank of America cut their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $89.11.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $62.58 on Wednesday. The firm has a market cap of $2.35 billion, a P/E ratio of -12.20 and a beta of 1.23. The stock’s 50-day moving average is $56.87 and its two-hundred day moving average is $51.89. Keros Therapeutics has a fifty-two week low of $27.31 and a fifty-two week high of $73.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Keros Therapeutics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock worth $870,000 after buying an additional 251 shares during the period. Ameritas Investment Partners Inc. increased its stake in Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares in the last quarter. Arizona State Retirement System increased its position in shares of Keros Therapeutics by 16.3% in the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after buying an additional 1,130 shares in the last quarter. American International Group Inc. raised its stake in Keros Therapeutics by 13.1% during the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock worth $838,000 after buying an additional 1,465 shares during the period. Finally, ProShare Advisors LLC grew its stake in Keros Therapeutics by 26.5% in the first quarter. ProShare Advisors LLC now owns 7,136 shares of the company’s stock valued at $472,000 after acquiring an additional 1,496 shares during the period. 71.56% of the stock is currently owned by institutional investors.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 22.90% of the stock is owned by company insiders.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.